Levels of renalase and advanced oxidation protein products with regard to catecholamines in haemodialysed patients
More details
Hide details
Department of Laboratory Diagnostic, Medical University of Lublin, Poland
Department of Nephrology, Medical University of Lublin, Poland
Department of Oral Medicine, Medical University of Lublin, Poland
Institute of Rural Health, Lublin, Poland
Corresponding author
Marcin Dziedzic   

Department of Laboratory Diagnostic, Medical University of Lublin, Poland
Ann Agric Environ Med. 2017;24(3):453-458
The main mediators of the sympathetic nervous system in the effectors part are catecholamines (CA). An increased sympathetic nerve activity observed in chronic kidney disease (CKD), is due to a raised level of CA in plasma. Renalase is a protein secreted by the kidneys, composed of 342 amino acids, which is able to metabolize the circulating CA and possibly play an important role in the regulation of sympathetic tone and blood pressure. Also, oxidative stress, defined as a disruption of the equilibrium between the generation of oxidants, is a crucial factor in the development of the inflammatory syndrome associated with CKD. The advanced oxidation protein products (AOPP) represent exquisite markers of phagocyte-derived oxidative stress.

The aim of the study was to investigate the concentration of renalase and explore the associations between AOPP with regards to CA in haemodialysis (HD) patients.

Material and Methods:
The study was conducted among 50 residents of the municipality and neighbouring villages in the province of Lublin, central-eastern Poland.

In the studied patients, it was found that an average concentration of renalase was 44.8 ± 6.5 μg/mL, whereas of AOPP plasma levels – 57.5 ± 21.5 μmol/L. The results demonstrated the correlation between levels of renalase and AOPP in the HD patients. Indeed, elevated levels of renalase and AOPP in HD may be due to the presence of uremic toxins in blood. The concentration of urea affects the plasma concentrations of AOPP and renalase causing a direct relationship between renalase and AOPP. However, there is no clear relationship between renalase and circulating catecholamines in HD patients

Axelord J, Weinshilboum R. Catecholamines. New Engl J Med. 1972; 2: 237–287.
Sarkar C, Chakroborty D, Basu S. Neurotransmitters as regulators of tumor angiogensis and immunity: the role of catecholamines. J Neuroimmune Pharmacol 2012; 10: 11481–11512.
Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005; 115(5): 1275–1280.
Moran GR. The catalytic function of renalase: A decade of phantoms. Biochim Biophys Acta. 2016; 1864(1): 177–86.
Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int. 2009; 76(4): 366–70.
Wu Y, Xu J, Velazquez H, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011; 79(8): 853–60.
Quelhas-Santos J, Pestana M. Plasma Renalase in Chronic Kidney Disease: Differences and Similarities between Humans and Rats Current Hypertension Reviews. 2014; 10: 166–170.
Salman IM. Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review. Curr Hypertens Rep. 2015; 17(8): 59.
Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl. 2003; 5(84): 11–4.
Buraczynska M, Zukowski P, Buraczynska K, Mozul S, Ksiazek A. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med. 2011; 13(4): 321–7.
Stec A, Ksiazek A, Buraczynska M. Rs10887800 renalase gene polymorphism is associated with an increased risk of coronary artery disease in hemodialyzed patients. Int Urol Nephrol. 2016; 48(6): 871–6.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373–383.
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1994; 4(5): 1205–1213.
Kopple JD; National Kidney Foundation K/DOQI Work Group. The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients. Am J Kidney Dis. 2001; 38: 68–73.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl. 2012; 2: 337–414.
Zadrazil J, Strebl P, Krejcí K, Horcicka V, Horák P, Vostálová J, Zdarilová A, Kajabová M, Schneiderka P. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clin Biochem. 2010; 43(6): 559–65. doi: 10.1016/j.clinbiochem.2010.01.003.
Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl. 2003; 84: 11–14.
Zhou Q, Wu S, Jiang J, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology (Carlton). 2012; 17(7): 642–9. doi: 10.1111/j.1440–1797.2012.01640.x.
Tagore R, Ling LH, Yang H, et al. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(6): 1644–1651.
Dziedzic M, Bednarek-Skublewska A, Solski J, Kapka-Skrzypczak L. Plasma and erythrocyte relationship of catecholamines in hemodialysis patients. Ann Agric Environ Med. 2014; 21(3): 562–6. doi: 10.5604/12321966.1120602.
Luft FC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab. 2005; 1(6): 358–360.
Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, Desir GV. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008; 117(10): 1277–82.
Zbroch E, Koc-Zorawska E, Malyszko J, Malyszko J, Mysliwiec M. Circulating levels of renalase, norepinephrine, and dopamine in dialysis patients. Ren Fail. 2013; 35(5): 673–9. doi: 10.3109/0886022X.2013.778754.
Dziedzic M, Ewelina O, Gawel K, Zawadzka M, Bednarek-Skublewska A, Solski J. Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients. Curr Issues Pharm Med Sci. 2014; 27(1): 37–40.
Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S. Renalase, kidney and cardiovascular disease: are they related or just coincidentally associated? Adv Med Sci. 2015; 60(1): 41–9.
Dziedzic M, Petkowicz B, Bednarek-Skublewska A, Solski J, Buczaj A, Choina P. Relationship between renalase and N-terminal pro-B-type natriuretic peptide (NT pro-BNP) in haemodialysis patients. Ann Agric Environ Med. 2014; 21(1): 132–5.
Zbroch E, Małyszko J, Małyszko J, Koc-Żórawska E, Myśliwiec M. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn. 2012; 122(1–2): 40–4.
Gu R, Lu W, Xie J, Bai J, Xu B. Renalase deficiency in heart failure model of rats--a potential mechanism underlying circulating norepinephrine accumulation. PLoS One 2011; 6(1): e14633.
Desir GV, Tang L, Wang P, Li G, Sampaio-Maia B, Quelhas-Santos J, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc 2012; 1(4): e002634.
Quelhas-Santos J, Sampaio-Maia B, Remião F, Serrão P, Soares-Silva I, Desir GV, Pestana M. Assessment of Renalase Activity on Catecholamines Degradation. The Open Hypertension Journal. 2015; 7: 14–18. doi: 10.2174/1876526201507010014.
Beaupre BA, Hoag MR, Roman J, Försterling FH, Moran GR. Metabolic function for human renalase: oxidation of isomeric forms of β-NAD(P)H that are inhibitory to primary metabolism. Biochemistry. 2015; 27; 54(3):795–806.
Quelhas-Santos J, Serrão MP, Soares-Silva I, Fernandes-Cerqueira C, Simões-Silva L, Pinho MJ, Remião F, Sampaio-Maia B, Desir GV, Pestana M. Renalase regulates peripheral and central dopaminergic activities. Am J Physiol Renal Physiol. 2015; 308(2): F84–91.
Malyszko J, Koc-Zorawska E, Zorawski M, Kozminski P, Zbroch E, Rysz J, Banach M, Malyszko JS. Renalase is removed by kidneys and during dialysis – excess related to CKD complications? Curr Vasc Pharmacol. 2015; 13(1): 134–40.
Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M. Hypertension and kidney disease: is renalase a new player or an innocent bystander? J Hypertens. 2012; 30(3): 457–62. doi: 10.1097/HJH.0b013e32834f0bb7.
Beaupre BA, Hoag MR, Moran GR. Renalase does not catalyze the oxidation of catecholamines. Arch Biochem Biophys. 2015; 1(579): 626. doi:10.1016/
Eikelis N, Hennebry SC, Lambert GW, Schlaich MP. Does renalase degrade catecholamines? Kidney Int. 2011; 79(12): 1380.
Wang F, Zhang G, Xing T, Lu Z, Li J, Peng C, Liu G, Wang N. Renalase contributes to the renal protection of delayed ischaemic preconditioning via the regulation of hypoxia-inducible factor-1α. J Cell Mol Med. 2015; 19(6): 1400–9. doi: 10.1111/jcmm.12527.
Moran GR. The catalytic function of renalase: A decade of phantoms. Biochim Biophys Acta. 2015; 18: 1570–9639(15)00107–7. doi: 10.1016/j.bbapap.2015.04.010.
Beaupre BA, Carmichael BR, Hoag MR, Shah DD, Moran GR. Renalase is an alpha-NAD(P)H oxidase/anomerase. J Am Chem Soc. 2013; 135(37): 13980–7.
Quelhas-Santos J. et al. Assessment of Renalase Activity on Catecholamines Degradation. Open Hypert J. 2015; 7: 14–18.
Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005; 115(5): 1275–80.
Wang F, Li J, Xing T, Xie Y, Wang N. Serum renalase is related to catecholamine levels and renal function. Clin Exp Nephrol. 2015; 19(1): 92–8.
Desir GV, Peixoto AJ Renalase in hypertension and kidney disease. Nephrol Dial Transplant. 2014; 29(1): 22–8.
Yin J, Lu Z, Wang F, Jiang Z, Lu L, Miao N, Wang N. Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy. J Cell Mol Med. 2016; 20(6): 1106–17.
Journals System - logo
Scroll to top